Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alnylam, Tekmira, Polyplus, and More

Premium

Title: RNA Interference Modulators of Hedgehog Signaling and Uses Thereof

Patent Number: 8,802,639

Filed: March 24, 2005

Inventor: David Bumcrot, Curis (Genentech)


Title: Oligonucleotides for RNA Interference and Biological Applications Thereof

Patent Number: 8,802,640

Filed: June 1, 2006

Lead Inventor: Jean-Paul Behr, Polyplus Transfection


Title: Lipid Formulation

Patent Number: 8,802,644

Filed: Jan. 25, 2012

Lead Inventor: Jianxin Chen, Tekmira Pharmaceuticals


Title: Amino Alcohol Cationic Lipids for Oligonucleotide Delivery

Patent Number: 8,802,863

Filed: Nov. 21, 2012

Lead Inventor: Brian Budzik, Sirna Therapeutics (Alnylam Pharmaceuticals)


Title: Methods and Compositions for Improved Delivery, Expression, or Activity of RNA Interference Agents

Patent Number: 8,802,138

Filed: April 11, 2012

Lead Inventor: Jessie Au, Optimum Therapeutics


Title: Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples

Patent Number: 8,802,599

Filed: June 23, 2011

Lead Inventor: Ranit Aharonov, Rosetta Genomics


Title: In Vivo Polynucleotide Delivery Conjugates Having Enzyme-sensitive Linkages

Patent Number: 8,802,773

Filed: March 15, 2013

Lead Inventor: David Rozema, Arrowhead Research


Title: miR-164 Gene That Controls Plant Root System Development and Fertility and Use Thereof

Patent Number: 8,802,929

Filed: Jan. 3, 2012

Lead Inventor: Lizhong Xiong, Huazhong Agricultural University

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.